Skip to main
XGN

Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc (XGN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Exagen is showing strong revenue growth and volume expansion, boosted by its expanded sales force and new biomarker launches. The company's focus on revenue cycle management and cost control initiatives, along with the potential for increased payment from commercial payors, demonstrate its commitment to maintaining positive cash flow. With a growing pipeline of biopharma deals and continued improvements in ASPs, Exagen's strong financial performance is expected to continue.

Bears say

Exagen is a commercial-stage diagnostics company with a focus on autoimmune diseases, specifically SLE and RA. The company's reliance on one operating segment and majority of its revenue being derived from sales of testing products increases the risk of the company's operations. Additionally, the company's financials show a lack of consistent profitability, with net losses reported in recent years.

Exagen Inc (XGN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exagen Inc (XGN) Forecast

Analysts have given Exagen Inc (XGN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Exagen Inc (XGN) has a Strong Buy consensus rating as of Aug 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exagen Inc (XGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.